Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection

Blood

Volumn 128, Issue 21, 2016, Pages 2527-2532

  Arcaini, Luca ^a,b   Besson, Caroline ^c   Frigeni, Marco ^a   Fontaine, Hélène ^d   Goldaniga, Maria ^e   Casato, Milvia ^f   Visentini, Marcella ^f   Torres, Harrys A ^g   Loustaud Ratti, Veronique ^h   Peveling Oberhag, Jan ⁱ   Fabris, Paolo ^j   Rossotti, Roberto ^k   Zaja, Francesco ^l   Rigacci, Luigi ^m   Rattotti, Sara ^b   Bruno, Raffaele ^a,b   Merli, Michele ⁿ   Dorival, Céline ^o   Alric, Laurent ^p   Jaccard, Arnaud ^h   Pol, Stanislas ^d   Carrat, Fabrice ^o,q   Valeria Ferretti, Virginia ^a   Visco, Carlo ^j   Hermine, Olivier ^d,r   more..

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c BICÊTRE HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h LIMOGES UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^j SAN BORTOLO HOSPITAL   (Italy)

^k OSPEDALE NIGUARDA CA GRANDA   (Italy)

^l Azienda Sanitaria Universitaria Friuli Centrale   (Italy)

^m AO Universitaria Careggi   (Italy)

ⁿ UNIVERSITY OF INSUBRIA   (Italy)

^o SORBONNE UNIVERSITÉ   (France)

^p UMR 152 IRD Universite Paul Sabatier   (France)

^q ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^r IMAGINE INSTITUTE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CRYOGLOBULIN; DACLATASVIR; DASABUVIR; DELEOBUVIR; FALDAPREVIR; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; CHRONIC HEPATITIS C; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPHOCYTIC LYMPHOMA; MALE; MARGINAL ZONE LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TISSUE SECTION; TREATMENT DURATION; WALDENSTROEM MACROGLOBULINEMIA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEPATITIS C, CHRONIC; LYMPHOMA, B-CELL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; SURVIVAL RATE;

ANTIVIRAL AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SOFOSBUVIR; SURVIVAL RATE;

EID: 85015085713     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-05-714667     Document Type: Article

References (31)

1. Saadoun D, Landau DA, Calabrese LH, Cacoub PP. Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology (Oxford). 2007;46(8): 1234-1242.
2. Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2006;15(11): 2078-2085.
3. de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol. 2008; 6(4):451-458.
4. Hermine O, Lefrère F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347(2): 89-94.
5. Arcaini L, Vallisa D, Rattotti S, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol. 2014;25(7):1404-1410.
6. Michot JM, Canioni D, Driss H, et al; ANRS HC-13 Lympho-C Study Group. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol. 2015;90(3):197-203.
7. American Association for the Study of Liver Diseases/Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. What's New and Updates/Changes: Wednesday, February 24, 2016. http://hcvguidelines.org.
8. European Association for Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63(1): 199-236.
9. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015;62(1 Suppl):S87-S99.
10. Carrier P, Jaccard A, Jacques J, et al. HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents. Liver Int. 2015;35(10): 2222-2227.
11. Rossotti R, Travi G, Pazzi A, Baiguera C, Morra E, Puoti M. Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report. J Hepatol. 2015;62(1):234-237.
12. Sultanik P, Klotz C, Brault P, Pol S, Mallet V. Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood. 2015;125(15): 2446-2447.
13. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology. 2007;18(6): 800-804.
14. Cheson BD, Fisher RI, Barrington SF, et al; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/ Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27): 3059-3067.
15. Hallek M, Cheson BD, Catovsky D, et al; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12): 5446-5456.
16. Asselah T, Boyer N, Saadoun D, Martinot- Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016; 36(suppl 1):47-57.
17. Suarez F, Lortholary O, Hermine O, Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107(8): 3034-3044.
18. Visco C, Finotto S. Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment. World J Gastroenterol. 2014; 20(32):11054-11061.
19. Besson C, Canioni D, Lepage E, et al; Groupe d'Etude des Lymphomes de l'Adulte Programs. Characteristics and outcome of diffuse large B- cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol. 2006;24(6):953-960.
20. Vallisa D, Bernuzzi P, Arcaini L, et al. Role of antihepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol. 2005; 23(3):468-473.
21. Peveling-Oberhag J, Arcaini L, Bankov K, Zeuzem S, Herrmann E. The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis. J Viral Hepat. 2016;23(7):536-544.
22. De Vita S, Sacco C, Sansonno D, et al. Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood. 1997;90(2):776-782.
23. Andreone P, Zignego AL, Cursaro C, et al. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med. 1998;129(4):294-298.
24. Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cryoglobulinemia Vasculitis. Am J Med. 2015;128(9):950-955.
25. Slager SL, Benavente Y, Blair A, et al. Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/ small lymphocytic lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014(48): 41-51.
26. Dreyling M, Thieblemont C, Gallamini A, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24(4): 857-877.
27. Tarella C, Arcaini L, Baldini L, et al. Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma). Clin Lymphoma Myeloma Leuk. 2015;15(2): 75-85.
28. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Non-Hodgkin's Lymphomas, NCCN Guidelines, Version 2.2016. https://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed 22 May 2016.
29. Torres HA, Mahale P. Most patients with HCV-associated lymphoma present with mild liver disease: a call to revise antiviral treatment prioritization. Liver Int. 2015;35(6): 1661-1664.
30. Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116(3):326-334; quiz 504-325.
31. Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010;116(3): 343-353.